Research Article

The Effect of PACS in Breast Tumor Diagnosis Based on Numerical Analysis

Guijun Guo and Yi Chen

Chongqing Red Cross Hospital (People’s Hospital of Jiangbei District) Department of Radiology, Chongqing 400020, China

Correspondence should be addressed to Yi Chen; chenyi19@zqshszhyy.wecom.work

Received 16 May 2022; Revised 8 June 2022; Accepted 11 June 2022; Published 13 July 2022

Academic Editor: Naeem Jan

Copyright © 2022 Guijun Guo and Yi Chen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The incidence and mortality rates are increasing year by year, and the incidence of the disease is gradually becoming younger [1–3]. In recent years, it has been found that the clinical outcome and prognosis of breast tumor are closely related to different molecular subtypes [4]. In clinical practice, the early identification of molecular subtypes [5].

Breast cancer is a malignant tumor that is genetically heterogeneous. There are some disparities in prognosis due to the varied biological behaviours of different molecular subtypes of breast tumor, which has been a hot issue of research both at home and abroad in recent years [6]. Many studies [7] have shown that the clinicopathological characteristics and prognosis of different molecular subtypes of breast tumor are significantly different. Molecular biology studies have confirmed the role of ER, PR, and HER-2 in the development of breast tumors, making them one of the most important reference indicators for assessing the biological behaviour of cancer cells and developing treatment plans [8]. The molecular pathology of luminal B breast tumor is characterized by ER-positive or/and PR-positive and HER-2 positive or negative but Ki–67 > 14% [9], and endocrine therapy is effective, while molecularly targeted therapy is feasible due to partial positive HER-2 expression. HER-2 overexpression type is effective for molecular targeted therapy but is prone to metastasis, high recurrence rate, and poor prognosis [10].

The triple negative type is resistant to both endocrine and molecular targeted therapy but is very aggressive and prone to metastasis and has the worst prognosis of all molecular subtypes. Early identification of diverse genetic subtypes of breast carcinoma is therefore critical in clinical practice for early and specific clinical treatment and prognosis [11, 12]. Results from prospective screening trials in European populations have shown that DBT as a stand-alone diagnosis or as an adjunct to digital mammography (DM) increases cancer detection rates by approximately 30% compared to DM alone [13]. The aim of this paper is to analyze the value of combining DM and DBT in the diagnosis of molecular subtypes of breast tumor and to provide a basis for more targeted clinical treatment planning [14].

The paper’s organization paragraph is as follows: the related work is presented in Section 2. Section 3 analyzes
the materials and methods of the proposed work. Section 4 discusses the experiments and results. Section 5 consists of the discussion; finally, in Section 6, the research work is concluded.

2. Related Work

Currently, the diagnosis of molecular subtypes of breast tumor is mainly based on surgical or puncture biopsy immunohistochemistry, which is the gold standard for the detection of ER, PR, HER-2, and Ki-67 expression, and the reliability of its tests also depends on the handling of the tissue, which may sometimes lead to false positives and false negatives [15]. Therefore, predicting the molecular subtype of breast tumor by imaging signs can further improve the reliability of preoperative treatment strategies, which is of great value for the precise treatment of breast tumor and improving the prognosis. With the development of imaging technology in recent years, DBT technology has played an important role in the diagnosis of breast tumor. DBT can clearly show the morphology, margins, and relationship with surrounding tissues of the lesion [16]. A simple lump is the most common and direct manifestation of breast tumor, and the results of this paper show that the majority of breast tumors present as simple lumps, with the main molecular subtype being luminal A. Burrs are a characteristic feature of invasive breast tumor, and their formation may be related to tumor pulling on the normal Cooper ligament or tumor invasion of invasive breast tumor, and their formation may be related to the boundaries.

In the study by [18], HER-2 types were most frequently seen as masses with calcification, followed by calcification alone, which is consistent with the results of this paper. [19] reported that breast tumors with HER-2 expression or amplification in molecular subtypes are more aggressive and difficult to treat, and malignant calcifications are more likely to develop in patients with HER-2 expression or amplification breast tumor. However, it has also been shown [20] that the presence of malignant calcification in breast tumor is not only associated with HER-2 expression or amplification but may also be related to other factors such as hormonal expression status. The results of this paper show that calcification is mainly seen in HER-2 expressing types and that DM combined with DBT does not improve the detection of calcification. However, it has also been reported that due to the abundance of glands in the breast, micro calcifications may be masked and DBT may reduce the interference of overlapping glands and improve the detection of calcifications.

In summary, the results of this paper suggest that DM combined with DBT is predictive of molecular subtypes of breast tumor and that certain imaging signs may be useful for preoperative individualization of treatment strategies and prognostic assessment.

3. Materials and Methods

3.1. General Information. Patients with breast tumor attending our hospital were selected. A total of 20 patients with 15 lesions were included in the analysis, all were female, aged 33-75 years, with a mean age of 52.6 ± 10.3 years. Inclusion criteria are as follows: (1) patients with breast tumor confirmed by puncture biopsy or surgical pathology and (2) mammography and DBT were performed before biopsy or surgery. Exclusion criteria are as follows: the quality of the images did not meet the diagnostic requirements. This work was approved by our hospital.

3.2. Inspection Methods. The Siemens Mammomat Inspiration completely digital mammography equipment is used to perform mammography in the cranio-caudal (CC) and mediolateral oblique (MLO) orientations. In each case, a single DM position is obtained, followed by an automatic DBT scan under the same compression conditions, in which the X-ray bulb is rotated over the breast and the breast is scanned from -25° to 25°, with automatic exposure every 2° of rotation, to obtain multiple low-dose X-ray images at different angles. The glandular thickness of the compressed breast determines the number of layers.

3.3. Image Analysis. The films were independently reviewed by two breast diagnosticians with associate or higher titles, and a consensus was reached after consultation. Breast tumor is described and evaluated on digital X-rays using the American College of Radiology’s Breast Imaging Reports and Data (BI-RADS) standard, which assesses the different imaging presentations of breast tumor, including masses, calcifications, masses with calcifications, and structural distortions.

4. Results

4.1. General Comparison. A total of 20 lesions were found in 15 breast tumor patients, of which 13 (35.5%) were luminal A. Radiographs showed 13 (54.3%) simple masses and 7 (23.7%) masses with calcification. The difference in the percentage of different molecular subtypes was statistically significant (P < 0.05), as shown in Table 1. Simple masses were the most common among the molecular subtypes, especially luminal A. The percentage of calcification alone was higher in the HER-2 overexpressing type, with 35 cases of calcification alone and 20 cases of HER-2 overexpressing type (57%), a statistically significant difference compared with the other three types (P < 0.05). The margins of the
masses were classified as clear, blurred, microlobulated, and burr-like (Figures 1–3), and the difference in the percentage of different molecular subtypes was statistically significant ($P < 0.05$), as shown in Table 2. The difference in the percentage of masses with clear margins was higher in the triple-negative type; the difference in the percentage of masses with indistinct margins was not statistically significant among the subtypes. The difference between PACS combined with DBT was statistically significant ($P < 0.05$), especially for masses with burr-like margins, as shown in Table 3 and Figures 1–3 showing specific examples.

Figures 1(a) and 1(b) are mammograms showing disorganisation of the external superior structures of the right breast with localised nodular changes. Figures 1(c) and 1(d) are mammograms of the breast.

The tomosynthesis shows a well-defined mass with segmental distribution of polymorphic calcifications. Triple negative invasive ductal carcinoma.

Figures 3(a) and 3(b) are mammograms showing a right supratentorial nodule with poorly defined margins. Figures 3(c) and 3(d) are tomosynthesis images of the mammary gland showing small nodules with well-defined margins and burrs. The nodules have well-defined margins with burrs and clearer signs of malignancy.

### 4.2. Comparison of Clinical Features

Benign breast tumors: MRI pattern is round, oval, or lobulated; uniform density; smooth, sharp margins; surrounding tissue shows halo signs, compression pushing; CT shows irregular or oval shape; well-defined borders; lobulated masses with burrs; tumor is denser than the gland on plain scan, but more clearly outlined on enhanced scan. Breast tumor: MRI is lobulated, nodular, or irregular; uneven density, infiltrative margins, burrs, surrounding invasion, irregular edematous bands, irregular margins; CT shows a confined lamellar lesion in the breast with no obvious mass shadow, higher density than the surrounding gland, unclear borders, significant calcification; infiltrative patients show flattened dense areas throughout the gland, with pinpoint edges of varying length.

The detection rate of breast tumor by MRI and CT was 95.21% and 96.37%, sensitivity was 98.74% and 98.21%, and specificity was 52.34% and 54.23%, with no statistically significant difference ($P > 0.05$); see Tables 4 and 5.

There was no statistically significant difference between CT and MR in the detection rates of LDC and IDC ($P > 0.05$); see Table 6.

### 5. Discussion

PACS is an important adjunct to the early diagnosis of breast tumor in clinical practice, as it can provide multisequence, multiparameter, multidirectional imaging with high soft tissue resolution and can effectively differentiate between benign and malignant tumors. In this study, 90 of the 98 patients with PACS-diagnosed breast tumors were ultimately diagnosed as breast tumors after pathological
Figure 2: (a) and (b) are mammograms. The mammogram shows an upper middle breast mass with poorly defined margins. (c) and (d) are tomosynthesis images of the breast showing radiolucent burrs around the mass with clear signs of malignancy.

Figure 3: Female, 68 years old. Luminal type A invasive ductal carcinoma.

| Mass margin    | Luminal type A | Luminal type B | HER-2 overexpression | Three yin types | $x^2$ | $P$   |
|----------------|----------------|----------------|----------------------|-----------------|------|------|
| Clear edge     | 6              | 7              | 0                    | 2               | 5.257| <0.001|
| Edge blur      | 1              | 2              | 4                    | 9               |      |      |
| Differential leaf | 3            | 1              | 5                    | 2               |      |      |
| Skin needling  | 3              | 2              | 3                    | 2               |      |      |
Most breast tumors appear as irregular low-signal masses at T1W1, while at T2W1, they appear as enhanced signals. The signal characteristics of the tumor are related to the internal composition of the tumor; the more collagen fibres the cells have, the more water they contain and the more pronounced their signal. Mucinous adenocarcinoma shows high signal due to the large amount of mucus and low signal due to calcification and collagen degeneration in the hard interstitium. Because the tumor tissue is not clearly distinguished from the lesion tissue due to congestion, oedema, and surrounding infiltration, oedematous bands with stellate borders might be seen. In cases of tumor invasion of the Cooper Tropic or skin, local indentation, or thickening of the skin, involvement of the nipple and milk ducts may be observed. The pectoralis major muscle and fascia may be involved when the tumor is more advanced. However, PACS has its limitations and is not good at detecting significant calcification in the lesion.

PACS has an important application in tumor diagnosis because of its high spatial and density resolution. In this study, the tumor density was slightly higher than that of the gland on PACS plain scan, and the PACS values were more variable on enhanced scan, which is consistent with previous studies, due to the abnormal metabolism of breast tumor, the varying degree of development, and the high iodine uptake by tumor cells [21].

The irregular shape of the tumor, with infiltrative growth and raised burr margins, often associated with lobular hyperplasia or dense mammary glands, makes it difficult to distinguish the mass from normal tissue and hyperplastic glands, which is also a major factor in misdiagnosis on CT. In this study, the diagnostic accuracy, sensitivity, and specificity of CT for breast tumor were 96.67%, 96.67%, and 54.54%, with five cases being misdiagnosed, and the misdiagnosis rate was slightly higher than that of PACS. In the remaining two cases, the extent of enhancement may be lower than the actual extent of cancer due to the strong dependence of cancer enhancement on tumor vascularity. In the present study, the detection rate of DCIS was statistically higher on CT than on MRI (\( P < 0.05 \)), while the detection rates of LDC and IDC on PACS were not statistically different (\( P > 0.05 \)).

DCIS is a malignant proliferation of epithelial cells in the ductal system of the breast, which is characterized microscopically by a poorly defined peribasal stromal infiltration.

### 6. Conclusions

However, PACS is not suitable for patients with metal prosthesis, pacemakers, obesity, and claustrophobia, while CT requires a certain amount of X-ray irradiation and may cause radiation damage. Furthermore, certain patients who are allergic to contrast chemicals are not candidates for PACS; thus, the clinical practice can select the most appropriate examination approach based on the patient’s current circumstances in order to increase the lesion’s detection rate. The accuracy and sensitivity of the test can also be improved by combining the tests.

### Data Availability

The dataset used in this paper are available from the corresponding author upon request.

### Conflicts of Interest

The authors declared that they have no conflicts of interest regarding this work.
References

[1] D. Fuster, J. Duch, P. Paredes et al., “Preoperative staging of large primary breast cancer with [18F]-fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures,” *Journal of Clinical Oncology*, vol. 26, no. 29, pp. 4746–4751, 2008.

[2] M. Pennant, Y. Takwoingi, L. Pennant et al., “A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence,” *Health Technology Assessment*, vol. 14, no. 50, pp. 1–103, 2010.

[3] J. L. Alberini, F. Lerebours, M. Wartski et al., “18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer,” *Cancer: Interdisciplinary International Journal of the American Cancer Society*, vol. 115, no. 21, pp. 5038–5047, 2009.

[4] R. Tang, M. Saksena, B. B. Koolen, M. J. T. Vrancken Peeters, T. S. Aukema et al., “Baseline diffusion-weighted imaging with the dual tracers fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) scanning in cancer,” *Journal of the National Comprehensive Cancer Network*, vol. 5, no. S1, p. S-1, 2007.

[5] N. C. Hodgson and K. Y. Gulenchyn, “Is there a role for positron emission tomography in breast cancer staging?”, *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 49, no. 3, pp. 992–1001, 2022.

[6] J. L. Alberini, F. Lerebours, M. Wartski et al., “18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer,” *Cancer: Interdisciplinary International Journal of the American Cancer Society*, vol. 115, no. 21, pp. 5038–5047, 2009.

[7] T. Komori, I. Narabayashi, K. Matsumura et al., “2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience,” *Annals of Nuclear Medicine*, vol. 21, no. 4, pp. 209–215, 2007.

[8] J. Morawitz, N. M. Bruckmann, F. Dietzel et al., “Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MI in patients with newly diagnosed breast cancer,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 49, no. 3, pp. 992–1001, 2022.

[9] D. A. Podoloff, R. H. Advani, C. Allred et al., “NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer,” *Journal of the National Comprehensive Cancer Network*, vol. 5, no. S1, p. S-1, 2007.

[10] N. C. Hodgson and K. Y. Gulenchyn, “Is there a role for positron emission tomography in breast cancer staging?”, *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 49, no. 3, pp. 992–1001, 2022.

[11] F. Puglisi, A. Follador, A. M. Minisini et al., “Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications,” *Annals of Oncology*, vol. 16, no. 2, pp. 263–266, 2005.

[12] S. Y. Choi, Y. W. Chang, H. J. Park, H. J. Kim, S. S. Hong, and D. Y. Seo, “Correlation of the apparent diffusion coefficient values on diffusion-weighted imaging with prognostic factors for breast cancer,” *The British Journal of Radiology*, vol. 85, no. 1016, pp. e474–e479, 2012.

[13] S. Mahner, S. Schirrmacher, W. Brenner et al., “Comparison between positron emission tomography using 2-[Fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer,” *Annals of Oncology*, vol. 19, no. 7, pp. 1249–1254, 2008.

[14] M. Akin, S. Orguc, F. Aras, and A. R. Kandiloglu, “Molecular subtypes of invasive breast cancer: correlation between PET/computed tomography and MRI findings,” *Nuclear Medicine Communications*, vol. 41, no. 8, pp. 810–816, 2020.